Earnings ·
Puma Biotechnology reports Q3 net income of $6M on $54.1M NERLYNX sales
PBYIPuma Biotechnology, Inc.
Puma Biotechnology reported third-quarter 2026 GAAP net income of $6.0 million, or $0.12 per basic share, compared to $8.8 million in the prior-year period. Total revenue reached $55.1 million, driven by $54.1 million in NERLYNX product sales and $1.0 million in royalties. The company raised its full-year 2026 net income guidance to $20–$22 million from a previous estimate of $17–$20 million. Puma Biotechnology is a biopharmaceutical company focused on the development and commercialization of innovative cancer therapies.